Search
Clinician Ordering Portal
Scientific evidence
The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can forego sentinel lymph node biopsy
Nov 2022
Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.
Publication: SKIN: Journal of Cutaneous Melanoma
A prospective, multi-center clinical utility study demonstrates that the 40-gene expression profile (40-GEP) test impacts clinical management for medicare-eligible patients with high-risk cutaneous squamous cell carcinoma (cSCC)
Nov 2022
The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) in the Medicare population are rapidly increasing. The current national guidelines are broad and the available staging systems for stratification are inadequate to accurately guide patient management.
Publication: Skin
The integrated 31-gene expression profile test (i31-GEP) for cutaneous melanoma outperforms the CP-GEP at identifying patients who can forego sentinel lymph node biopsy when applying NCCN guidelines
Nov 2022
Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.
Publication: SKIN: Journal of Cutaneous Melanoma
Improving patient selection for adjuvant therapy: considerations for the role of the 31-gene expression profile test
Oct 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the Society for Melanoma Research Conference, Edinburgh Scotland, October 17-20 2022
Independent validation of TissueCypher to predict progression in community-based Barrett’s esophagus with low grade dysplasia: analysis in a completed prospective study (podium presentation at UEG 2020 annual meeting OP017)
Oct 2022
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.
Publication: United European Gastroenterology Journal
An objective spatialomics test standardizes management decisions with potential to improve outcomes for Barrett’s esophagus patients
Oct 2022
This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows how TissueCypher can aid in consistency of BE management.
Publication: Podium presentation (S386) at ACG 2022, Charlotte
Pharmacogenomic testing and depressive symptom remission: A systematic review and meta-analysis of prospective, controlled clinical trials
Sep 2022
Real-world evidence shows clinicians appropriately use the prognostic 40-gene expression profile (40-GEP) test for high-risk cutaneous squamous cell carcinoma (cSCC) patients
Sep 2022
Treatment decisions for patients with cutaneous squamous cell carcinoma (cSCC) are traditionally based upon clinicopathologic risk factors and staging systems. Due to the accuracy limitations of these resources in predicting poor outcomes, there is a clinically significant need for more accurate methods of risk assessment.
Publication: Cancer Investigation
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test
Jul 2022
Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS.
Publication: Journal of the American Academy of Dermatology
An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low-grade dysplasia
May 2022
Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.
Publication: Podium presentation (695) at DDW 2022, San Diego
Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders
May 2022
An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia
Apr 2022
Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.
Publication: Podium presentation (OP079) at ESGE 2022, Prague